Last reviewed · How we verify

NU100 — Competitive Intelligence Brief

NU100 (NU100) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: S1P1 receptor modulator. Area: Multiple Sclerosis.

phase 3 S1P1 receptor modulator S1P1 Multiple Sclerosis Biologic Live · refreshed every 30 min

Target snapshot

NU100 (NU100) — Nuron Biotech Inc.. NU100 is a small molecule that targets the S1P1 receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
NU100 TARGET NU100 Nuron Biotech Inc. phase 3 S1P1 receptor modulator S1P1
fingolimob (FTY) fingolimob (FTY) University Hospital, Clermont-Ferrand marketed Sphingosine-1-phosphate receptor modulator S1P1 receptor (sphingosine-1-phosphate receptor 1)
FTY720 FTY720 Novartis Pharmaceuticals marketed Sphingosine-1-phosphate receptor modulator; Immunomodulator Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)
Group S+T Group S+T Huazhong University of Science and Technology marketed S1P receptor modulator S1P1
RO0503821 (1x/4 Weeks) RO0503821 (1x/4 Weeks) Hoffmann-La Roche phase 3 S1P receptor modulator S1P1
KP-100IT KP-100IT Kringle Pharma, Inc. phase 3 S1P1 receptor modulator S1P1
RPC1063 RPC1063 Celgene phase 3 S1P receptor modulator S1P1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (S1P1 receptor modulator class)

  1. AbbVie · 1 drug in this class
  2. Archigen Biotech Limited · 1 drug in this class
  3. AstraZeneca · 1 drug in this class
  4. BioLineRx, Ltd. · 1 drug in this class
  5. Bright Minds Biosciences Pty Ltd · 1 drug in this class
  6. Celtic Pharma Development Services · 1 drug in this class
  7. Daewoong Pharmaceutical Co. LTD. · 1 drug in this class
  8. Eric Stephen Winer, MD · 1 drug in this class
  9. Ferrer Internacional S.A. · 1 drug in this class
  10. GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NU100 — Competitive Intelligence Brief. https://druglandscape.com/ci/nu100. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: